GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (XTAE:CANF) » Definitions » Cyclically Adjusted PB Ratio

Can Fite Biofarma (XTAE:CANF) Cyclically Adjusted PB Ratio : 0.05 (As of May. 16, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Can Fite Biofarma Cyclically Adjusted PB Ratio?

As of today (2024-05-16), Can Fite Biofarma's current share price is ₪0.027. Can Fite Biofarma's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was ₪0.56. Can Fite Biofarma's Cyclically Adjusted PB Ratio for today is 0.05.

The historical rank and industry rank for Can Fite Biofarma's Cyclically Adjusted PB Ratio or its related term are showing as below:

XTAE:CANF' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.04   Med: 0.18   Max: 0.5
Current: 0.05

During the past years, Can Fite Biofarma's highest Cyclically Adjusted PB Ratio was 0.50. The lowest was 0.04. And the median was 0.18.

XTAE:CANF's Cyclically Adjusted PB Ratio is ranked better than
93.19% of 646 companies
in the Biotechnology industry
Industry Median: 1.76 vs XTAE:CANF: 0.05

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Can Fite Biofarma's adjusted book value per share data for the three months ended in Dec. 2023 was ₪0.017. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ₪0.56 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Can Fite Biofarma Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Can Fite Biofarma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Cyclically Adjusted PB Ratio Chart

Can Fite Biofarma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.32 0.25 0.14 0.05

Can Fite Biofarma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.05 0.07 0.06 0.05

Competitive Comparison of Can Fite Biofarma's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Can Fite Biofarma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Can Fite Biofarma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Can Fite Biofarma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Can Fite Biofarma's Cyclically Adjusted PB Ratio falls into.



Can Fite Biofarma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Can Fite Biofarma's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.027/0.56
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Can Fite Biofarma's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Can Fite Biofarma's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.017/129.4194*129.4194
=0.017

Current CPI (Dec. 2023) = 129.4194.

Can Fite Biofarma Quarterly Data

Book Value per Share CPI Adj_Book
201403 1.174 99.695 1.524
201406 0.831 100.560 1.069
201409 0.525 100.428 0.677
201412 1.124 99.070 1.468
201503 1.039 99.621 1.350
201506 0.796 100.684 1.023
201509 1.190 100.392 1.534
201512 1.378 99.792 1.787
201603 1.229 100.470 1.583
201606 1.014 101.688 1.291
201609 0.780 101.861 0.991
201612 0.515 101.863 0.654
201703 0.656 102.862 0.825
201706 0.448 103.349 0.561
201709 0.392 104.136 0.487
201712 0.556 104.011 0.692
201803 0.687 105.290 0.844
201806 0.602 106.317 0.733
201809 0.585 106.507 0.711
201812 0.276 105.998 0.337
201903 0.267 107.251 0.322
201906 0.313 108.070 0.375
201909 0.218 108.329 0.260
201912 0.075 108.420 0.090
202003 0.000 108.902 0.000
202006 0.082 108.767 0.098
202009 0.076 109.815 0.090
202012 0.048 109.897 0.057
202103 0.051 111.754 0.059
202106 0.028 114.631 0.032
202109 0.057 115.734 0.064
202112 0.065 117.630 0.072
202203 0.054 121.301 0.058
202206 0.045 125.017 0.047
202209 0.034 125.227 0.035
202212 0.020 125.222 0.021
202303 0.026 127.348 0.026
202306 0.021 128.729 0.021
202309 0.016 129.860 0.016
202312 0.017 129.419 0.017

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Can Fite Biofarma  (XTAE:CANF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Can Fite Biofarma Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Can Fite Biofarma (XTAE:CANF) Business Description

Traded in Other Exchanges
Address
10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778
Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Can Fite Biofarma (XTAE:CANF) Headlines

From GuruFocus

Can-Fite BioPharma Announces $6 Million Registered Direct Offering

By Marketwired Marketwired 05-20-2019